Table 2 Analytical results of the antimalarial samples purchased from the informal market in Congo, Burundi and Angola.
From: Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials
Sample1 | Packaging/Exp. Date2 | Origin3 | % Assay (%RSD) | Uniformity of Mass | Disintegration Test | % Dissolved4 (%RSD) |
|---|---|---|---|---|---|---|
Qc1 | In the "Essential Drugs Programme-WHO" pot/02-2007 | Cyprus | 97.0 (0.9) | IS | IS | 98 (1) |
Qc4 | loose tablets/08-2008 | Congo | 99.8 (0.4) | IS | IS | 96 (1) |
Qc6 | loose tablets/07-2007 | Holland | 102.7 (0.7) | IS | IS | 100 (2) |
Qc10 | loose tablets/04-2008 | Congo | 100.3 (0.8) | IS | IS | 96 (2) |
Qc11 | loose tablets/10-2007 | Congo | 99.5 (0.7) | OOS | IS | 96 (1) |
Qc12 | loose tablets/08-2006 | Congo | 98.5 (0.2) | IS | IS | 101 (1) |
Qc14 | loose tablets/NA | NA4 | 96 (2) | IS | IS | 75 (5) OOS |
Qc17 | loose tablets/NA | NA | 88.6 (0.6) OOS | IS | IS | 58 (7) OOS |
Qc18 | loose tablets/NA | NA | 97.4 (0.8) | IS | IS | 72.3 (0.6) OOS |
Qc20 | in blister/01-2007 | India | 95.2 (0.4) | IS | IS | 99 (4) |
Qb1 | loose tablets/11-2009 | NA | 99.0 (0.5) | IS | IS | 96 (1) |
Qb4 | in blister/05-2008 | Burundi | 99 (1) | IS | IS | 101 (2) |
Qb5 | loose tablets/05-2008 | NA | Different Active | OOS | IS | 30 (8) OOS |
Qb6 | loose tablets/03-2008 | NA | 95.9 (0.3) | IS | IS | 88 (4) |
Qa3 | in blister and secondary packaging/08-2008 | India | 97.4 (0.8) | IS | IS | 50 (5) OOS |
Qa5 | in blister/10-2007 | India | 98 (1) | IS | IS | 98 (2) |
Ma4 | in blister/06-2006 | Brazil | 102.6 (0.9) | IS | IS | Not evaluated |
Ma6 | in blister and secondary packaging/08-2007 | Cyprus | 102.4 (0.8) | Not evaluated | Not evaluated | Not evaluated |
Ca1 | in blister and secondary packaging/08-2007 | India | 102 (2) | IS | IS | 26 (3) OOS |
Ca2 | in blister/08-2007 | India | 102.8 (0.7) | IS | IS | 75 (7) OOS |
% Dissolved 5 (%RSD) | ||||||
SPc2 | tablets loose/11-2006 | Malta | S = 94.8 (0.6) | IS | IS | S = 79.5 (0.2) |
P = 99.1 (0.1) | P = 73 (2) | |||||
SPc3 | in blister and secondary packaging/06-2007 | India | S = 96.3 (0.3) | IS | IS | S = 97 (5) |
P = 100.3 (0.2) | P = 67.9 (0.6) | |||||
SPc5 | in blister and secondary packaging/02-2007 | India | S = 98 (1) | IS | IS | S = 99 (1) |
P = 100.9 (0.6) | P = 72 (1) | |||||
SPc7 | tablets loose/10-2008 | Cyprus | S = 95.9 (0.6) | IS | IS | S = 95 (3) |
P = 97.9 (0.4) | P = 73 (3) | |||||
SPc8 | tablets loose/NA | NA | S = 94.0 (0.2) | IS | IS | S = 57 (3) OOS |
P = 94.1 (0.6) | P = 24 (1) OOS | |||||
SPc9 | in blister and secondary packaging/06-2007 | India | S = 96 (1) | IS | IS | S = 84 (3) |
P = 102.7 (0.1) | P = 52 (2) OOS | |||||
SPc13 | loose tablets/NA | NA | S = 93.3 (0.4) | IS | IS | S = 80.6 (0.7) |
P = 104.6 (0.6) | P = 53 (7) OOS | |||||
SPc15 | loose tablets/NA | NA | S = 95 (1) | IS | IS | S = 72 (1) |
P = 100.7 (0.9) | P = 45 (3) OOS | |||||
SPc16 | loose tablets/NA | NA | S = 97.3 (0.2) | IS | IS | S = 95 (1) |
P = 100.8 (0.5) | P = 55 (5)OOS | |||||
SPc19 | in blister/NA | China | S = 93.8 (0.4) | IS | IS | S = 47 (2)OOS |
P = 99.1 (0.8) | P = 18.6 (0.6)OOS |